Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files
暂无分享,去创建一个
Jens Loesel | Jeremy R Everett | James Mills | Marie-Claire Peakman | Hongyao Zhu | Andrew S Bell | Joseph Bradley | David McLoughlin | Robert E Sharp | Christine Williams | Jens Loesel | J. Everett | M. Peakman | A. Bell | Christine Williams | Hongyao Zhu | David McLoughlin | Joseph Bradley | James Mills | R. Sharp | A. Bell
[1] N. Meanwell. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.
[2] E. Kwong,et al. Advancing drug discovery: a pharmaceutics perspective. , 2015, Journal of pharmaceutical sciences.
[3] Jürgen Bajorath,et al. Virtual compound screening in drug discovery. , 2012, Future medicinal chemistry.
[4] Gisbert Schneider,et al. Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.
[5] Fabrizio Giordanetto,et al. Potential strategies for increasing drug-discovery productivity. , 2014, Future medicinal chemistry.
[6] Asher Mullard,et al. 2015 FDA drug approvals , 2016, Nature Reviews Drug Discovery.
[7] S. Planey,et al. The influence of lipophilicity in drug discovery and design , 2012, Expert opinion on drug discovery.
[8] Christopher W Murray,et al. Efficient exploration of chemical space by fragment-based screening. , 2014, Progress in biophysics and molecular biology.
[9] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[10] Valerie J. Gillet,et al. Diversity selection algorithms , 2011 .
[11] Highly Potent , Selective , and E ffi cacious Metabotropic Glutamate Receptor 5 ( mGluR 5 ) Negative Allosteric Modulator , 2014 .
[12] Kevin R Clark,et al. Small-Molecule Library Subset Screening as an Aid for Accelerating Lead Identification , 2014, Journal of biomolecular screening.
[13] Willem P. van Hoorn,et al. Designing Compound Subsets: Comparison of Random and Rational Approaches Using Statistical Simulation , 2007, J. Chem. Inf. Model..
[14] Albert J. Leo,et al. Calculating log P(oct) with no missing fragments; The problem of estimating new interaction parameters , 2000 .
[15] Brendan Connolly,et al. Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry. , 2008, Analytica chimica acta.
[16] Andreas Larsson,et al. Efficiency of hit generation and structural characterization in fragment-based ligand discovery. , 2011, Current opinion in chemical biology.
[17] A. Harvey,et al. The re-emergence of natural products for drug discovery in the genomics era , 2015, Nature Reviews Drug Discovery.
[18] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[19] Eddy Arnold,et al. Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery. , 2014, Progress in biophysics and molecular biology.
[20] Andrew Bell,et al. Shaping a Screening File for Maximal Lead Discovery Efficiency and Effectiveness: Elimination of Molecular Redundancy , 2012, J. Chem. Inf. Model..
[21] Andreas Bender,et al. Plate-Based Diversity Selection Based on Empirical HTS Data to Enhance the Number of Hits and Their Chemical Diversity , 2009, Journal of biomolecular screening.
[22] Vinicius M Alves,et al. Virtual screening strategies in medicinal chemistry: the state of the art and current challenges. , 2014, Current topics in medicinal chemistry.
[23] György M. Keserü,et al. The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.
[24] Anne Mai Wassermann,et al. Biodiversity of small molecules--a new perspective in screening set selection. , 2013, Drug discovery today.
[25] D. Pereira,et al. Origin and evolution of high throughput screening , 2007, British journal of pharmacology.
[26] Lorenz M Mayr,et al. Novel trends in high-throughput screening. , 2009, Current opinion in pharmacology.
[27] P. Chanda,et al. A fluorescence-based assay for monoacylglycerol lipase compatible with inhibitor screening. , 2008, Assay and drug development technologies.
[28] John P. Overington,et al. Probing the links between in vitro potency, ADMET and physicochemical parameters , 2011, Nature Reviews Drug Discovery.
[29] Julian Blagg,et al. Structure–Activity Relationships for In vitro and In vivo Toxicity , 2006 .
[30] Jens Loesel,et al. Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file , 2013, Molecular Diversity.
[31] Roman Boutellier,et al. Design principles for innovative workspaces to increase efficiency in pharmaceutical R&D: lessons learned from the Novartis campus. , 2013, Drug discovery today.
[32] Hualin Xi,et al. The design, annotation, and application of a kinase-targeted library. , 2011, Methods in molecular biology.
[33] Ricardo Macarron,et al. Enhancements of screening collections to address areas of unmet medical need: an industry perspective. , 2010, Current opinion in chemical biology.
[34] Tarek A. Leil,et al. Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development , 2014, Front. Pharmacol..
[35] K. M. Smith,et al. Novel software tools for chemical diversity , 1998 .
[36] Tian Zhu,et al. Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. , 2013, Journal of medicinal chemistry.
[37] J. Scannell,et al. Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.
[38] Andreas Bender,et al. “Plate Cherry Picking”: A Novel Semi-Sequential Screening Paradigm for Cheaper, Faster, Information-Rich Compound Selection , 2007, Journal of biomolecular screening.
[39] W. Janzen,et al. Screening technologies for small molecule discovery: the state of the art. , 2014, Chemistry & biology.
[40] M. Breyer. Improving productivity of modern-day drug discovery , 2014, Expert opinion on drug discovery.
[41] Diane Joseph-McCarthy,et al. Fragment-Based Lead Discovery and Design , 2014, J. Chem. Inf. Model..
[42] Asher Mullard. 2014 FDA drug approvals , 2015, Nature Reviews Drug Discovery.
[43] F. Pullen,et al. The application of non-combinatorial chemistry to lead discovery. , 2001, Drug discovery today.
[44] S. Rees,et al. Principles of early drug discovery , 2011, British journal of pharmacology.
[45] Bert L. de Groot,et al. Conformational Transitions upon Ligand Binding: Holo-Structure Prediction from Apo Conformations , 2010, PLoS Comput. Biol..
[46] John L. LaMattina,et al. The impact of mergers on pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.
[47] F. Sams-Dodd,et al. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. , 2013, Drug discovery today.
[48] R. Slusser,et al. The Paradox of Scientific Excellence and the Search for Productivity in Pharmaceutical Research and Development , 2014, Clinical pharmacology and therapeutics.
[49] F. Pammolli,et al. The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.
[50] Jordi Mestres,et al. Coverage and bias in chemical library design. , 2008, Current opinion in chemical biology.
[51] Nigel Greene,et al. Physicochemical drug properties associated with in vivo toxicological outcomes: a review , 2009, Expert opinion on drug metabolism & toxicology.
[52] Gregory A. Bakken,et al. A Heuristic Algorithm for Plate SelectionThat Maximizes Compound Diversity , 2013 .